Abstract
Phosphorylated proteins represent one of the most important constituents of the proteome and are under intense analysis by the biotechnology and pharmaceutical industry because of their central role for cellular signal transduction. Indeed, alterations in cellular signaling and control mechanisms that modulate signal transduction, functionally underpin most human cancers today. Beyond their central role as the causative components of tumorigenesis, these proteins have become an important research focus for discovery of predictive and prognostic biomarkers. Consequently, these pathway constituents comprise a powerful biomarker subclass whereby the same analyte that provides prediction and/or prognosis is also the drug target itself: a theranostic marker. Reverse phase protein microarrays have been developed to generate a functional patient-specific circuit “map” of the cell signaling networks based directly on cellular analysis of a biopsy specimen. This patient-specific circuit diagram provides key information that identifies critical nodes within aberrantly activated signaling that may serve as drug targets for individualized or combinatorial therapy. The protein arrays provide a portrait of the activated signaling network by the quantitative analysis of the phosphorylated, or activated, state of cell signaling proteins. Based on the growing realization that each patient’s tumor is different at the molecular level, the ability to measure and profile the ongoing phosphoprotein biomarker repertoire provides a new opportunity to personalize therapy based on the patient-specific alterations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Faivre S, Djelloul S, Raymond E. (2006) New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. 1: Semin Oncol. 33(4):407–20.
Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, et al. (2007) Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA. 31;104(31):12867–72.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 18;316(5827):1039–43.
Sawyers CL. (2008) The cancer biomarker problem. Nature. 3;452(7187):548.
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. (2008) An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science 26;321(5897):1807–12.
Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. Sep. 26;321(5897):1801–6.
Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science. 16;318(5853):1108–13.
Liotta LA, Kohn EC, and Petricoin EF. (2001) Clinical proteomics: personalized molecular medicine. JAMA. 286(18):2211–4.
Petricoin EF 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L. et al. (2005) Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol. 23:3614–21.
Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF. (2006) Technology Insight: pharmacoproteomics for cancer-promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol. 3(5):256–68.
Anderson L, Seilhamer J.(1997) A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18(3–4):533–7.
Gygi SP, Rochon Y, Franza BR, Aebersold R. (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 19(3): 1720–30.
Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud Ø, Gjertsen BT, et al. (2004) Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 23;118(2):217–28.
Irish JM, Anensen N, Hovland R, Skavland J, Børresen-Dale AL, Bruserud O, et al. (2007) Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood. 15;109(6):2589–96.
Stern DF. (2005) Phosphoproteomics for oncology discovery and treatment. Expert Opin Ther Targets. 9(4):851–60.
Moran MF, Tong J, Taylor P, Ewing RM. (2006) Emerging applications for phospho-proteomics in cancer molecular therapeutics. 1: Biochim Biophys Acta. Dec 1766(2):230–41.
Hunter, T. (2000) Signaling-2000 and beyond. Cell 100, 113–127.
Figlin RA. (2008) Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. Nat Clin Pract Oncol. 5(10):601–9.
Jin Q, Esteva FJ. (2008) Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia. 13(4):485–98.
Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, Harsha HC, et al. (2008) Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA. 105(37):14112–7.
Cui Q, Ma Y, Jaramillo M, Bari H, Awan A, Yang S, et al. (2007) A map of human cancer signaling. Mol Syst Biol. 3:152.
Haura EB, Zheng Z, Song L, Cantor A, Bepler G. (2005) Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 11(23):8288–94.
Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. (2007) Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 19(10):2013–23.
Swanton C, Futreal A, Eisen T. (2006) Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res. 12(14 Pt 2):4377s–4383s.
Casalini P, Iorio MV, Galmozzi E, Ménard S. (2004) Role of HER receptors family in development and differentiation. J Cell Physiol. 200(3):343–50.
Wiley HS. (2003) Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res. 284(1):78–88.
Arteaga CL.(2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 7 Suppl 4:31–9.
Smock RG, Gierasch LM. (2009) Sending signals dynamically. Science. 324(5924):198–203.
Ventura AC, Jackson TL, Merajver SD. (2009) On the role of cell signaling models in cancer research. Cancer Res. 69(2):400–2.
Araujo RP, Liotta LA, Petricoin EF. (2007) Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov. 6(11):871–80.
Geho DH, Petricoin EF, Liotta LA, Araujo RP. (2005) Modeling of protein signaling networks in clinical proteomics. Cold Spring Harb Symp Quant Biol. 70:517–24.
Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. (2010) Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res. Jul 19. [Epub ahead of print].
Araujo RP, Liotta LA. (2006) A control theoretic paradigm for cell signaling networks: a simple complexity for a sensitive robustness. Curr Opin Chem Biol. 10(1):81–7.
Araujo RP, Petricoin EF, Liotta LA. (2005) A mathematical model of combination therapy using the EGFR signaling network. Biosystems. 80(1):57–69.
Napoletani D, Sauer T, Struppa DC, Petricoin E, Liotta L. (2008) Augmented sparse reconstruction of protein signaling networks. J Theor Biol. 255(1):40–52.
Johnson SA, Hunter T. (2005) Kinomics: methods for deciphering the kinome. Nat Methods. 2(1):17–25.
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 4(12):988–1004.
O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66(3):1500–8.
Grünwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J. (2009) Molecular targeted therapies for solid tumors: management of side effects. Onkologie. 32(3):129–38.
Huang Z, Brdlik C, Jin P, Shepard HM. (2009) A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther. 9(1):97–110.
Ramos JW. (2008) The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol. 40(12):2707–19.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773(8):1263–84.
Paweletz CP, Charboneau L, Roth MJ, Bichsel VE, Simone NL, Chen T, et al. (2001) Reverse phase proteomic microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 12;20(16):1981–9.
Pierobon M, Calvert V, Belluco C, Garaci E, Deng J, Lise M, et al. (2009) Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. Clin Colorectal Cancer. 8(2):110–7.
Gulmann C, Sheehan KM, Conroy RM, Wulfkuhle JD, Espina V, Mullarkey MJ, et al. (2009) Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. J Pathol. 218(4):514–9.
Vanmeter AJ, Rodriguez AS, Bowman ED, Harris CC, Deng J, Calvert VS, et al. (2008) LCM and protein microarray analysis of human NSCLC: Differential EGFR phosphorylation events associated with mutated EGFR compared to wild type. Mol Cell Proteomics. 7(10):1902–24.
Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, et al. (2008) Multiplexed Cell Signaling Analysis of Human Breast Cancer: Applications for Personalized Therapy. J of Prot Res. 7(4):1508–17.
Sanchez-Carbayo M, Socci ND, Richstone L, Corton M, Behrendt N, Wulkfuhle J, et al. (2007) Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression. Am J Pathol. 171(5):1650–8.
Zhou, J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. PNAS. 104(41):16158–63.
Sheehan KM, Gulmann, C, Eichler GS, Weinstein, J, Barrett HL, Kay EW, et al. (2007) Signal Pathway Profiling of Epithelial and Stromal Compartments of Colonic Carcinoma Reveal Epithelial-Mesenchymal Transition Oncogene. 27(3):323–31.
Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, et al. (2007) The needle in the haystack: Application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer. 111(3):173–84.
Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X, et al. (2007) Phosphoprotein Signal Pathway Mapping: Akt/mTOR Pathway Activation Association with Childhood Rhabdomyosarcoma Survival. Cancer Research. 67(7):3431–4.
Calvert VS, Tang Y, Boveia V, Wulfkuhle J, Schutz-Geschwender Olive DM, et al. (2004) Development of Multiplexed Protein Profiling and Detection Using Near Infrared Detection of Reverse-Phase Protein Microarrays. Clinical Proteomics. 1(1):81–90.
Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, et al. (2005) Use of reverse-phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics. 4, 346–55.
Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. (1996) Laser capture microdissection. Science. 274(5289):998–1001.
Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, et al. (2010) Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest. 90(5):787–96.
Avninder S, Ylaya K, Hewitt SM. (2008) Tissue microarray: a simple technology that has revolutionized research in pathology. J Postgrad Med. 54(2):158–62.
Haab BB. (2005) Antibody arrays in cancer research. Mol Cell Proteomics. 4(4):377–83.
Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E 3rd, Liotta LA et al. (2004) Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest. 84, 235–44.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Pierobon, M., Belluco, C., Liotta, L.A., Petricoin, E.F. (2011). Reverse Phase Protein Microarrays for Clinical Applications. In: Korf, U. (eds) Protein Microarrays. Methods in Molecular Biology, vol 785. Humana Press. https://doi.org/10.1007/978-1-61779-286-1_1
Download citation
DOI: https://doi.org/10.1007/978-1-61779-286-1_1
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-285-4
Online ISBN: 978-1-61779-286-1
eBook Packages: Springer Protocols